Deals

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
Astellas PharmaAudax Biosciences

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Pharma Inc. (TYO: 4503) and Audax Biosciences Pty Ltd jointly announced that the two parties have entered into an exclusive option and license agreement for DAX-044, Audax's lead oncology…

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CVDFinance

JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products

CRO / CMO / CDMOFinance

ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion

BiotechFinance

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development

AstraZenecaCancer

mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC

Show More